grant

Advanced Development of a Combined Shigella-ETEC Vaccine

Organization UNIVERSITY OF MARYLAND BALTIMORELocation BALTIMORE, UNITED STATESPosted 9 Jun 2023Deadline 31 May 2028
NIHUS FederalResearch GrantFY20250-11 years oldAdvanced DevelopmentAnimal ModelAnimal Models and Related StudiesAntigensAntimicrobial ResistanceArmed Forces PersonnelAttenuatedAttenuated VaccinesBiological AgentBiological ProductsChildChild YouthChildren (0-21)ChromosomesClinicalClinical EvaluationClinical TestingClinical TrialsCombination VaccinesCombined VaccinesConsultationsDataDedicationsDeveloping CountriesDeveloping NationsDevelopmentDiarrheaDiseaseDisorderDocumentationE coli VaccinesE. coli VaccinesETECEarly-Stage Clinical TrialsEngineeringEnsureEnterotoxinsEscherichia coli VaccinesExcretory functionFermentationFormulationFundingFunding MechanismsGenesGoalsGood Manufacturing ProcessGood manufacturing practiceGroups at riskHumanImmune responseIn VitroIndustrializationInterventionInvestigational DrugsInvestigational New DrugsLaboratory ResearchLeadLess-Developed CountriesLess-Developed NationsLive-attenuated VaccineMilitaryMilitary PersonnelMissionModern ManModificationNIAIDNational Institute of Allergy and Infectious DiseaseOrganismPatternPb elementPeople at riskPerformancePersons at riskPhase 1 Clinical TrialsPhase 2 Clinical TrialsPhase I Clinical TrialsPhase II Clinical TrialsPlasmidsPopulationPopulations at RiskPrincipal InvestigatorProceduresProcessProductionResearch InstituteS flexneriS sonneiS. flexneriS. sonneiSafetySeriesShigellaShigella VaccinesShigella flexneriShigella sonneiTarget PopulationsTestingThird-World CountriesThird-World NationsToxinTranslatingUnder-Developed CountriesUnder-Developed NationsVaccine ProductionVaccinesVialVial deviceVirulenceVisitVulnerable PopulationsWorkanti-microbial resistantattenuateattenuatesbiologicsbiopharmaceuticalbiotherapeutic agentburden of diseaseburden of illnesscell bankclinical testcolonization factor antigensconsultationdeploy vaccinesdevelop a vaccinedevelop vaccinesdeveloping countrydeveloping nationdevelopment of a vaccinedevelopmentaldiarrheal diseasediarrheal illnessdisease burdendistribute vaccinesdrug lot productionenteral pathogenenteric pathogenenteropathogenenterotoxigenic E colienterotoxigenic E. colienterotoxigenic E.colienterotoxigenic Escherichia coliexcretionexperienceheavy metal Pbheavy metal leadhost responseimmune response to vaccinationimmune response to vaccinesimmune system responseimmunogenimmunogenicimmunogenicityimmunoresponsein vivointestinal pathogenintestine pathogenkidslive vaccinelive vaccinesliving systemlot productionmanufacturemilitary populationmodel of animalnovelpathogenphase I protocolphase II protocolpre-clinicalpre-clinical studypreclinicalpreclinical studypreventpreventingproduce vaccinesprogramsprotective efficacyprototyperesearch clinical testingresistance to anti-microbialresistant to antimicrobialscale upsuccessvaccine associated immune responsevaccine candidatevaccine deploymentvaccine developmentvaccine distributionvaccine immune responsevaccine immunogenicityvaccine induced immune responsevaccine roll-outvaccine rolloutvulnerable groupvulnerable individualvulnerable peopleyoungster
Sign up free to applyApply link · pipeline · email alerts
— or —

Get email alerts for similar roles

Weekly digest · no password needed · unsubscribe any time

Description preview

Program Director/Principal Investigator (Last, First, Middle): Barry, Eileen M.
Project Summary

Shigella and enterotoxigenic Escherichia coli (ETEC) are two of the most important diarrheal pathogens

worldwide, causing significant disease in young children in developing countries and in U.S. travelers, including

military personnel, who visit…

🔒

Full details available on the Agency plan

Unlock the complete grant description, eligibility criteria, contract value, evaluation details and apply link — plus alerts, pipeline tracking, and CSV export.

Start 7-day free trial — $29.99/mo →

Agency Plan

7-day free trial

Unlock procurement & grants

Upgrade to access active tenders from World Bank, UNDP, ADB and more — with email alerts and pipeline tracking.

$29.99 / month

  • 🔔Email alerts for new matching tenders
  • 🗂️Track tenders in your pipeline
  • 💰Filter by contract value
  • 📥Export results to CSV
  • 📌Save searches with one click
Start 7-day free trial →
Advanced Development of a Combined Shigella-ETEC Vaccine — UNIVERSITY OF MARYLAND BALTIMORE | UNITED STATES | Jun 2023 | Dev Procure